Other promising new therapeutic targets in BPDCN include CD38, HA-1H, CD56, and ILT3, but little has been reported about their potential use in the pediatric population [120]. This evidence concerns the gene NCAM1 and CD4+/CD56+ hematodermic neoplasm.